TrialInvestigational new drugs2017

Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.

Yuichi Tambo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.